Russian Direct Investment Fund expect the process of gradual expertise for further registration of the Sputnik V coronavirus vaccine in the EU will commence in February, the Fund representative said Wednesday.
"The Direct Investment Fund confirms that, yesterday, the experts from the European Medicines Agency (EMA) conducted a scientific review for the Sputnik V vaccine developers. Over 20 international experts and scientists participated in the meeting. The recommendations obtained during the discussion will be forwarded to the Sputnik V developers within 7 to 10 days. The Fund filed an application for vaccine registration and expects the rolling review to commence in February," TASS cited the representative as saying.
The European Agency will decide on registration of the vaccine following a series of expert checks, the Fund said.
The Sputnik V vaccine is already registered in Russia, Belarus, Serbia, Argentina, Bolivia, Algeria, Palestine, Venezuela, Paraguay and Turkmenistan.
On January 22, the World Health Organization will commence the pre-submission review procedure for the Sputnik V.
